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OBJECTIVE: Description of some of the clinical pathological characteristics of neuroendocrine tumors of the
gastroenteropancreatic tract in Brazilian patients.
INTRODUCTION: Neuroendocrine tumors arise in many organs and share common pathological features. In 2010,
the World Health Organization published a new classification for neuroendocrine tumors using a three-tiered
system that applies the terms neuroendocrine tumor Grade 1, neuroendocrine tumor Grade 2, and neuroendocrine
carcinoma. The tumor grades are based on their mitotic rate and the Ki-67 index. In Brazil, information on
neuroendocrine tumors of gastroenteropancreatic tract is scarce.
METHODS: This study investigated clinicopathological features of 773 Brazilian gastroenteropancreatic neuroendo-
crine tumor cases from all the geographic regions of Brazil. All of the cases emerged from the files of a single
institution (a large pathology reference laboratory) between 1997 and 2009. In addition, the gastroenteropan-
creatic neuroendocrine tumors were graded according to the new 2010 World Health Organization classification.
RESULTS: Overall there were a higher number of neuroendocrine tumors in female over male. The lower ages were
seen in patients with appendiceal tumors. The most common anatomic location involved was stomach followed by
small and large intestines. All cases involving the appendix were of grade 1 and 92.1% of the neuroendocrine
tumors of the esophagus were neuroendocrine carcinomas (grade 3).
CONCLUSIONS: In this series, the proportion of NET cases in the total number of surgical pathology cases at our
institution over the past 12 years is increasing.
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INTRODUCTION
Neuroendocrine tumors (NETs) are a heterogeneous group
of neoplasms composed of cells containing dense-core
neuroendocrine secretory granules in their cytoplasm. These
tumors are relatively rare and display a diverse spectrum of
clinical presentation. Recent data from the SEER (Surveillance,
Epidemiology, and End Results Program, USA) suggest that
the incidence and prevalence of NETs have increased
substantially over the past three decades. The main explana-
tion for this increase is improved awareness of the disease
among physicians, including pathologists, and improved
diagnostic techniques. The incidence may also be increasing,
but the evidence that supports this is unclear.1Approximately
two-thirds of NETs are found in the gastrointestinal tract, one-
quarter occur in the lungs, and the remaining cases arise in
other endocrine tissues, such as the thyroid.2,3 These tumors
account for approximately 2% of all malignancies of the
gastrointestinal tract. Esophageal NETs are rare, and the
majority are high grade, i.e., neuroendocrine carcinoma
(NEC).4 In an analysis of 8,305 NETs at different anatomical
sites, only three (0.04%) were reported in the esophagus.4,5 In
the past, gastric NETs have been reported to account for 2 to
3% of all gastrointestinal NETs.6 Recent studies, however,
have suggested that the incidence of these tumors might be
higher, as much as 11 to 41% of all gastrointestinal NETs,
depending on the series.4 Neuroendocrine carcinomas account
for 6 to 16% of gastric neuroendocrine neoplasms.4
In the duodenum, neuroendocrine neoplasms constitute 5.7
to 7.9% of the neuroendocrine neoplasms of the digestive
tract, and the proximal jejunum accounts for approximately
1% of gut neuroendocrine neoplasms.4,6 NETs of the cecum
and transverse colon represent approximately 8% of all
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gastrointestinal NETs, while NETs of the descending colon
and rectosigmoid combined represent approximately 27%.2,4,5
NETS in the gastrointestinal tract occur predominantly in
the small intestine (44.7%), followed by the rectum (19.6%),
appendix (16.7%), colon (10.6%), and stomach (7.2%).7
Pancreatic NETs (PETs) are uncommon, representing 1 to
2% of all pancreatic neoplasms. Pancreatic NECs account for
less than 1% of all pancreatic carcinomas and less than 3% of
all pancreatic neuroendocrine neoplasms.4
The previous World Health Organization (WHO) classi-
fications for NETs of the tubular gastrointestinal tract
(WHO, 2000) and pancreas (WHO, 2004) used a hybrid
classification system that incorporated both staging and
histological grading information into a single prognostic
prediction system.8-11 The 2010 WHO classification, which
was developed along with the European Neuroendocrine
Tumor Society (ENETS), uses two separate and comple-
mentary classification tools —histological grading and a
site-specific staging system.4,12-17
There is limited information about the gastroenteropancrea-
tic NETs (GEP-NETs) that occur in Brazil.3,18,19,20 The purpose
of this study was to describe some of the clinicopathological
aspects of 773 GEP-NETs in Brazilian patients using the newly
published WHO 2010 classification of NETs.
MATERIALS AND METHODS
Case Selection
A total of 773 NETs cases were obtained retrospectively
from the cases in the files of Consultoria em Patologia (a large
anatomical pathology reference consultation service in
Botucatu, Sa˜o Paulo State, Brazil) dating from January
1997 to December 2009. Clinical data, including gender, age
at diagnosis, and anatomic locations, were obtained for all
of the GEP-NETs cases. The 2010 WHO NET classification
system was applied to all of GEP-NETs, using hematoxylin
and eosin-stained slides and the immunohistochemistry
(MIB1 monoclonal antibodies against the Ki-67 antigen) cell
proliferation index, as described previously.21-24
The pathological diagnoses of the NETs in this series
considered the typical morphological findings and the
expression of neuroendocrine markers, including chromo-
granin A and/or synaptophysin, as described previously.25
According to the WHO 2010 classification and the ENETS
scheme,4,16,17 the grades were assigned as follows: G1 (NET
G1/carcinoid), with a mitotic count of ,2 per 10 high power
fields (HPF) and/or a Ki-67 index#2%; G2 (NET G2), with a
mitotic count of 2 to 20 per 10 HPF and/or a Ki-67 index of 3
to 20%; and G3 (neuroendocrine carcinoma), with a mitotic
count of .20 per 10 HPF and/or a Ki-67 index .20%
(Figures 1 and 2). The grading used in this study followed the
practice of countingmitotic figures in at least fifty high power
fields and using the percentage of 500 to 2000 cells counted in
the areas with the strongest MIB1 antibody nuclear labeling
(‘‘hot spots’’) as the Ki-67 index.4 In cases where the amount
of tumor tissue was limited and an accurate mitotic count
was not possible, the grading was based on the Ki-67 index
alone. In cases where the mitotic count and the Ki-67 index
grades differed, the highest grade was recorded. It was not
possible to apply a site-specific staging system in this study;
inmost cases, the gross description of the tumor, including its
size, was not available.
Figure 1 - A) A G1 neuroendocrine tumor (hematoxylin-eosin, X200). Note the uniformity and the characteristic organoid growth
pattern. B) A G2 neuroendocrine tumor (hematoxylin-eosin, X200). Mild atypia and coarser chromatin are observed. C) A
neuroendocrine carcinoma (hematoxylin-eosin, X200). Note the cellular atypia and frequent mitotic figures.
Figure 2 - A) A low cell-proliferation index (Ki-67,2%) in a G1 neuroendocrine tumor (X400). B) An intermediate cell-proliferation
index (Ki-67,10%) in a G2 neuroendocrine tumor (X400). C) A high cell-proliferation index (Ki-67,90%) in a G3 neuroendocrine
carcinoma (X400).
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RESULTS
All the results are summarized in Table 1.
Esophagus, Stomach, and Pancreas NETs
Forty (5%) of the 773 GEP-NET cases were located in the
esophagus, with the vast majority of the cases (92.1%) being
G3 (NECs) (age range = 47 to 85 years; mean= 63.4 years).
Esophageal NETs were more prevalent in men (71%).
Dysphagia was the most frequently reported symptom.
One hundred ninety cases (24.5%) were located in the
stomach. Most of the cases (84.7%) were well-differentiated
NETs (G1= 76.3%; G2= 8.4%; age range= 24 to 87 years;
mean=54 years). Women represented 61.9% of these cases.
‘‘Polyp’’ was the major endoscopic finding. The tumor sizes
ranged from 0.3 to 8.5 cm (average = 1.8 cm).
In the pancreas, a total of 126 (16.4%) NECs accounted for
8% of the pancreatic NETs, compared to 92% well-
differentiated NETs (64.5% were G1, and 27.5% were G2)
(age range= 22 to 82 years; mean age = 52.1 years), and 59%
occurred in females. Hypoglycemia and diarrhea were
the most frequent related symptoms. There was only one
reported case of increased serum gastrin levels, which was
confirmed by immunohistochemistry. The tumor sizes
ranged from 0.3 to 8.0 cm (average = 2.6 cm).
Intestinal NETs
In the small intestine (161 cases or 20.8%), G1 was the
most frequent tumor type (84.4%), followed by G2 (8.1%)
and G3 (7.5%). The mean age at diagnosis was 57.9 years
(age range = 25 to 88 years). Women were affected slightly
more frequently (57.7%). The mean tumor size was 2.4 cm
(size range= 0.4 to 7.0 cm).
In the colon (43 cases or 5.5%), the NET grades were
divided as follows: G1, 51.1%; G2, 16.3%; and G3, 32.6%.
The mean age was 55.7 years (age range= 31-81 years).
Females accounted for 67.5% and males for 32.5% of the
cases. Most of the colon tumors were polyps. The rectal
NETs (161 or 20.5%) included 77.3% G1, 6.3% G2, and 16.4%
G3; the patients’ mean age was 50 years, with a range of 27
to 88 years. Rectal NETs were slightly more prevalent in
women (59.1%). Hematochezia was the most frequent
complaint. The tumor sizes ranged from 0.4 to 5.0 cm
(average= 1.4 cm). Appendix NETs (56 cases or 7.3%)
occurred at a significantly younger age than did the NETS
at other sites, with a mean age at presentation of 27.6 years
(range = 8 to 71 years). They were all G1 tumors and
presented more frequently in women (59%). Abdominal
pain was the most common complaint.
In the 773 study cases, the average age was 52.8 years, and
57.7% of the patients were female. The stomach was the
most commonly involved anatomic site (190 cases or 24.5%),
followed by the small intestine (161 cases or 20.8%) and the
rectum (159 cases or 20.5%). The esophagus was the least
commonly affected organ (38 cases or 5%).
DISCUSSION
NETs, which are defined as epithelial neoplasms with
predominant neuroendocrine differentiation, arise in most
organs. Most NETs develop in the gastrointestinal tract and
bronchopulmonary tree.1,26
Although NETs have been considered a fairly rare
disease, the SEER database suggests that their prevalence
has increased dramatically over the last three decades. In
fact, it is believed that the incidence of these tumors is
increasing globally. It is likely that this increase is due to an
increase in the actual number of cases and/or increased
clinical and pathological experience with diagnosing this
disease.26 In this series, we found that the proportion of
NET cases in the total number of surgical pathology cases at
our institution over the past 12 years is increasing (Table 2).
Overall, the gastrointestinal tract represents the site of
greatest NET incidence (64.3%), followed by the broncho-
pulmonary system (27.9%).27 Approximately 0.46% of all
malignancies are NETs of bronchopulmonary or gastro-
intestinal origin. GEP-NETs are substantially less common
than their counterpart, adenocarcinomas; the incidence is
approximately two to five cases per 100,000.2 Unfortunately,
information regarding the incidence or prevalence of GEP-
NETs in Brazil is virtually nonexistent.
NETs of the esophagus are rare, representing only 0.04%
of all the gastrointestinal NETs reported.4,5,28 The literature
clearly shows that NETs in this anatomical location occur
more frequently in males in the sixth and seventh decades
of life (mean age= 56 years), as our study confirms.
Table 1 - The distribution of the 773 GEP-NETcases by anatomical location, gender, age, and grading.
Anatomic
Location N˚ of cases Male Female
Age range
(average) Grade G1 Grade G2 Grade G3
Esophagus 38 (5%) 27 (71%) 11 (29%) 47-85 (63.4) 3 (7.9%) 0 (0%) 35 (92.1%)
Stomach 190 (24.5%) 74 (38.1%) 116 (61.9%) 24-87 (54) 145 (76.3%) 16 (8.4%) 29 (15.3%)
Pancreas 126 (16.4%) 52 (40.9%) 74 (59.1%) 22-82 (52.1) 81 (64.5%) 35 (27.5%) 10 (8%)
Small intestine 161 (20.8) 72 (44.7%) 89 (55.3%) 25-88 (57.7) 136 (84.4%) 13 (8.1%) 12 (7.5%)
Colon 43 (5.5%) 14 (32.5%) 29(67.5%) 31-81 (55.7) 22 (51.1%) 7 (16.3%) 14 (32.6%)
Rectum 159 (20.5%) 65 (40.9%) 94 (59.1%) 27-88 (50) 123 (77.3%) 10 (6.3%) 26 (16.4%)
Appendix 56 (7.3%) 23 (41%) 33 (59%) 8-71 (27.6) 56 (100%) 0 (0%) 0 (0%)
Total 773 (100%) 327 (42.3%) 446 (57.7%) 8-88 (52.8) 566 (73.2%) 81 (10.5%) 126 (16.3%)
Table 2 - The distribution of the number and percentage of GEP-NET cases from 1997 to 2009 per three-year period and
their percentage out of the total number of surgical pathology cases from a single pathology institution.
1997-1999 2000-2002 2003-2005 2006-2009 1997-2009
Number (%) of GEP-NETs 27 (0.18%) 104 (0.30%) 186 (0.35%) 456 (0.50%) 773 (0.40%)
Total number of surgical
pathology cases
14,393 34,492 52,820 89,705 191,410
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Additionally, the literature clearly shows that the vast
majority of NET cases involving the esophagus are indeed
of high grade, as was also seen in our study.4,5 In our series,
only three of the 38 esophageal NETs were low-grade (G1),
and all of the remaining cases were NECs.
According to Modlin et al.30, gastric NETs account for
approximately 6% of all gastrointestinal NETs. Most gastric
NETs are well differentiated and nonfunctional. Three distinct
types are recognized: Type I, associated with autoimmune
atrophic gastritis; Type II, associated with multiple endocrine
neoplasia Type 1 (MEN-1) and Zollinger-Ellison (SZE); and
Type III, sporadic. Unfortunately, we were unable to classify
the gastric NETs into these different types because we had
only biopsy material for each case and not the entire specimen
or detailed clinical information. In our series, the stomach was
the site most frequently affected (196 cases or 24.5%) by GEP-
NETs. Similar findings have been described recently by Yildiz
et al.30 Most of our gastric NET cases were well-differentiated
G1 and G2 neoplasms (84.7%) rather than high grade tumors
(NECs), which are rarely found in the stomach.4 Inmost series,
the most frequent anatomic location of GEP-NETs is the
appendix. We believe that appendix NETs were not the most
frequent type in our series because our cases were seen in
consultation. Most pathologists are more comfortable diag-
nosing NETs in the appendix than in other anatomic locations.
PETs are rare and represent one to two percent of all
pancreatic cancers. In our study, they represented 16.4% of all
the GEP-NETs. Pancreatic NETs have no sex predilection and
occur in a broad age range (30 to 60 years).10 In our study, we
found a slightly higher prevalence in women (59.1%). Based
on their clinical manifestations, PETs can be separated into
functioning and nonfunctioning tumors. Functioning tumors
are associated with clinical syndromes caused by inappropri-
ate synthesis of hormones: insulinomas (27.2%), gastrinomas
(12.5%), glucagonomas (8%), VIPomas (6.4%), and somatos-
tatinomas (3.8%).10 Nonfunctioning tumorsmake up 39.7% of
PETs. In our series, clinical information on tumor hormone
production was available in only one case, which was
hypergastrinemia. It is interesting to note that the vast
majority of our PET cases were graded G1 or G2. High-grade
PETs are also rare. We found 64.5% G1s, 27.5% G2s, and 8%
G3s (neuroendocrine carcinomas-NEC) among our cases.
According to a Swedish study, the incidence of all intestinal
NETs is approximately 2.0/100,000 for men and 2.4/100,000
for women.31 NETs of the small intestine have site-related
differences that depend on their anatomical locations. NETs of
the duodenum and jejunum represent 22% of all gastrointest-
inal endocrine malignancies.12 They commonly present in the
sixth decade of life with symptoms of abdominal pain or
bowel obstruction. Typical carcinoid syndromes are rare,
manifesting in approximately 5 to 7% of patients. In our series,
the small intestine was the second most affected site (161
cases). As seen in our series, themajority of intestinal NETs are
well differentiated and nonfunctioning. NECs are rare and
more often affect the ampulla of Vater.
NETs are found in three to nine of every 1,000 appendec-
tomies, but they usually behave as benign neoplasms. They
account for 50% of abdominal NETs. According to some
series, 19% of GI NETs are located in the appendix.4,5 They
are the most common tumors of the appendix, far out
numbering adenocarcinomas. As in our series, the mean age
at presentation is usually younger (32-43 years) than for other
gastrointestinal tract NETs, and they are more common in
women.4,5,32-34 Probably reflecting the good prognosis of
NETs involving the appendix, all of our appendiceal NETs
were well differentiated (G1).
NETs located from the cecum to the transverse colon
represent approximately 8% of all gastrointestinal NETs,
while NETs of the descending and rectosigmoid and colon
combined represent approximately 27%.2,4,5 They are found
incidentally in one out of 2,500 proctoscopies and are
usually smaller than one centimeter. Their sex distribution
is equal, and the average age at diagnosis is 56 years for
rectal NETs and 66 years for colonic NETs.4 In our series, we
observed a higher frequency in women (67.5% for colonic
and 59.1% for rectal NETs). NECs are rare in the large
bowel, representing approximately 0.6% of all carcinomas in
this location. Nevertheless, they are more common there
than in any other part of the intestine.4
A NET diagnosis is based on the clinical presentation and
the blood hormonal profile, and it is always confirmed and
classified by a pathologist.10,35 An immunohistochemical
study is essential to confirm the neuroendocrine differentia-
tion of neoplastic cells and define the primary site of
metastatic NETs.25,36 Furthermore, immunohistochemistry
is useful for evaluating the production of hormones by the
neoplasm and the rate of cell proliferation through Ki-67
expression.21-24
Our series is a descriptive study of some of the clinical
and pathologic characteristics of GEP-NETs, based on the
files of a single institution. To our knowledge, it represents
the first overview study of GEP-NETs in Brazilian patients.
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